{"product_id":"qgen-bcg-matrix","title":"(QGEN) Qiagen N.V. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Qiagen N.V. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The page already shows a real preview of the actual report content, so you can review what you’ll get before buying. Purchase the full version to access the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQIAstat-Dx syndromic PCR panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQIAstat-Dx syndromic PCR panels are QIAGEN’s clearest growth engine in clinical testing. The menu covers respiratory, gastrointestinal, and other multiplex panels, so each new system can drive recurring reagent sales. With an expanding installed base and broader assay use, it looks like a strong Star candidate by end-2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQIAcuity digital PCR systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, QIAcuity stayed QIAGEN’s key dPCR growth engine, with adoption widening in research, translational, and clinical workflows. That fits a Star: fast market growth and rising penetration, not a mature cash cow. QIAGEN kept expanding the QIAcuity menu and placements through 2025, supporting share gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNGS library prep and gene panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQIAGEN's NGS stack spans library prep kits, whole genome amplification, and predefined and custom panels. NGS keeps growing fast in oncology, hereditary testing, and applied genomics, so this unit fits a Stars slot in the BCG Matrix. QIAGEN has a real base here, but it still needs heavy R\u0026amp;D and commercial spend to defend share and widen its panel menu.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompanion diagnostics partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQIAGEN's companion diagnostics ties with Sysmex, OncXerna Therapeutics, and Mirati keep its precision-oncology pipeline active, and this fits a Stars profile: high growth with rising share. These assays help match patients to biomarker-driven therapies, which is where oncology testing demand is growing fastest. QIAGEN reported $2.0 billion in 2024 revenue, giving it scale to push more co-developed tests.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePartners: Sysmex, OncXerna, Mirati.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFocus: biomarker-based treatment selection.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eEdge: collaborations expand assay share.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBioinformatics software and digital insight tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQIAGEN’s software layer is a Star-like asset because it sits on top of growing molecular diagnostics and genomics workflows, where every extra sequencing or PCR run raises the need for interpretation. It also scales well: software adds recurring value without the same lab capex as instruments. QIAGEN’s latest filing showed about $2.0bn in annual sales, with software helping lift mix and stickiness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth workflow layer\u003c\/li\u003e\n\u003cli\u003eRecurring, scalable economics\u003c\/li\u003e\n\u003cli\u003eSupports cross-sell and retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQIAGEN’s Growth Engines: QIAstat-Dx and QIAcuity Lead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQIAGEN’s Stars are QIAstat-Dx and QIAcuity, with NGS and companion diagnostics also scaling in fast-growing markets. QIAstat-Dx and QIAcuity had the clearest 2025 growth profile, while QIAGEN’s 2024 revenue was about $2.0bn, giving it room to fund share gains.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQIAstat-Dx\u003c\/td\u003e\n\u003ctd\u003eMultiplex PCR growth\u003c\/td\u003e\n\u003ctd\u003eInstalled-base expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQIAcuity\u003c\/td\u003e\n\u003ctd\u003edPCR adoption rising\u003c\/td\u003e\n\u003ctd\u003eMenu and placement growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQiagen's BCG Matrix maps its diagnostics portfolio to spot stars, cash cows, question marks, and dogs for smart capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Qiagen N.V. that quickly spots growth and drag areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Qiagen N.V. that speeds due diligence and strengthens confidence in key assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSample prep kits for nucleic acid purification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSample prep kits for nucleic acid purification remain one of QIAGEN’s largest, most mature cash cows, with demand spread across research, diagnostics, and applied testing. The franchise benefits from recurring consumable sales from both manual and automated workflows, which supports steady cash generation even when unit growth slows. In QIAGEN’s latest reported results, this kind of recurring revenue base helped keep margins resilient and cash flow durable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuantiFERON-TB Gold Plus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuantiFERON-TB Gold Plus is Qiagen’s leading interferon-gamma release assay for latent TB, and it sits in a mature testing market with durable, repeat demand from labs and clinics. Its large installed base and global use support steady cash flow, while the category’s scale matters given WHO still estimates about 1.25 million TB deaths in 2023. That is classic Cash Cow territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eqPCR and RT-PCR consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQIAGEN's qPCR and RT-PCR consumables are a classic cash cow: labs use these reagents in gene expression, genotyping, and regulation studies every run, so demand is sticky and repeat-heavy. In FY2025, QIAGEN generated about $2.0 billion in net sales, and this consumables base helps support that steady cash flow with low reinvestment needs. Growth is modest, but the installed customer base keeps volumes recurring and margins resilient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHuman ID and forensic STR assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQIAGEN’s Human ID and forensic STR assays are a classic cash cow: mature, niche workflows with repeat kit demand from forensic labs. This supports sticky sales and margin discipline more than fast growth. In 2024, QIAGEN reported net sales of about $2.1 billion and adjusted diluted EPS of $2.20.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat consumables drive revenue.\u003c\/li\u003e\n\u003cli\u003eSpecialized lab workflows cut churn.\u003c\/li\u003e\n\u003cli\u003eFocus is retention, not expansion.\u003c\/li\u003e\n\u003cli\u003eStable cash flow supports margins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOEM consumables and repeat-use lab materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQIAGEN's OEM consumables and repeat-use lab materials are classic cash cows: they are built into partner workflows, so demand is sticky and repeat orders keep coming. In 2024, QIAGEN generated about $1.97 billion in net sales, and this mature, installed-base business helps fund growth bets with steady cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring demand from embedded workflows\u003c\/li\u003e\n\u003cli\u003eLow churn versus one-off instrument sales\u003c\/li\u003e\n\u003cli\u003eStable cash, not high-growth upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQIAGEN’s Recurring Revenue Engine Runs on Mature Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQIAGEN’s cash cows are mature consumables with repeat demand, led by sample prep kits, qPCR and RT-PCR reagents, QuantiFERON-TB Gold Plus, and Human ID assays. These lines sell into installed lab workflows, so churn is low and cash flow is steady. In FY2025, QIAGEN reported about $2.0 billion in net sales, showing the scale of this recurring base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSample prep kits\u003c\/td\u003e\n\u003ctd\u003eRepeat consumables\u003c\/td\u003e\n\u003ctd\u003eSteady sales base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuantiFERON-TB Gold Plus\u003c\/td\u003e\n\u003ctd\u003eMature TB testing\u003c\/td\u003e\n\u003ctd\u003eWHO: 1.25M TB deaths in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eQiagen N.V. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Qiagen N.V. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content or hidden sections—just the full, professionally formatted report. Once purchased, it’s ready to download, use, and share right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy standalone PCR instrument lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy standalone PCR instrument lines sit in a crowded market, where larger platform vendors push higher-throughput systems and bundled consumables. Compared with newer digital and multiplex PCR tools, growth is modest and the installed base is mainly a harvest pool, not an expansion engine. QIAGEN’s newer QIAcuity and syndromic testing lines are the growth focus, while these older instruments keep cash but face slower demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder manual purification accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder manual purification accessories sit in the Dogs quadrant because they support legacy prep workflows that are being displaced by automation. These add-ons are usually commoditized, low-margin, and tied to shrinking installed bases, so their strategic share and growth stay weak versus Qiagen N.V.'s higher-value sample technologies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFood contamination testing assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFood contamination testing assays sit in a fragmented, price-sensitive applied market, so they fit as a Dog in Qiagen N.V.'s BCG Matrix. QIAGEN does participate, but this niche is not a core growth engine; in FY2025, the company’s focus stayed on diagnostics and genomics, where scale and margins are stronger. That makes food testing a low-priority use of capital versus higher-return areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall prenatal and STD niche menus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQIAGEN N.V.'s small prenatal and STD niche menus look like Dogs by end-2025: they sit in crowded assay markets, face uneven reimbursement, and do not have the scale or brand pull of QuantiFERON. In QIAGEN's 2025 mix, these lines are likely low-growth, low-share pockets rather than core value drivers. Their role is more defensive than expansionary.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow share, weak growth.\u003c\/li\u003e\n\u003cli\u003eHeavy pricing pressure.\u003c\/li\u003e\n\u003cli\u003eReimbursement stays uneven.\u003c\/li\u003e\n\u003cli\u003eNot QuantiFERON-scale assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes them better candidates for harvest, tight cost control, or selective pruning than for major reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-volume custom lab service work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQIAGEN N.V.’s low-volume custom lab service work fits Dogs: it is bespoke, hard to scale, and usually brings limited repeat demand. Compared with consumables and platform sales, it has weaker margin leverage and less strategic pull, so it is a poor target for major capital spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow scale, low repeat demand\u003c\/li\u003e\n\u003cli\u003eWeak margin leverage\u003c\/li\u003e\n\u003cli\u003eCapital-light only\u003c\/li\u003e\n\u003cli\u003eBest kept niche or trimmed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQIAGEN’s Dog Products: Legacy, Pressured, and Deprioritized\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in QIAGEN N.V.'s BCG mix are legacy PCR tools, manual prep add-ons, food testing assays, and small niche menus: low share, weak growth, and heavy price pressure. In FY2025, QIAGEN kept capital on QuantiFERON, QIAcuity, and syndromic testing, so these lines are harvest or prune candidates.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog set\u003c\/th\u003e\n\u003cth\u003eFY2025 read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy PCR\u003c\/td\u003e\n\u003ctd\u003eLow growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManual prep\u003c\/td\u003e\n\u003ctd\u003eCommoditized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFood testing\u003c\/td\u003e\n\u003ctd\u003ePrice pressured\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLiquid biopsy and cfDNA oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLiquid biopsy and cfDNA oncology is a Question Mark: the market is still growing at roughly 15%-20% a year, but Qiagen N.V. is not the share leader. With about €2.0 billion revenue in 2024, Qiagen has tools and partnerships, yet it still needs investment to turn promise into durable scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustom NGS panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCustom NGS panels fit a Question Mark for Qiagen N.V. because precision-medicine and translational-research demand is rising, but the field is crowded and Qiagen is still building share. Qiagen reported 2024 net sales of US$1.98 billion, yet custom panels need more scale to win against bigger NGS rivals. Growth is real, but so is the fight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader oncology mutation, insertion, deletion, and fusion assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBroader oncology mutation, insertion, deletion, and fusion assays sit in a fast-growing market: IARC counted 20 million new cancer cases in 2022, and cases may reach 35 million by 2050. QIAGEN has strong products, but share is not dominant across all targets, so this is still a Question Mark in BCG terms. It needs steady sales, menu expansion, and partner wins to avoid slipping toward Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNext-gen decentralized testing expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQIAGEN is pushing sample-to-insight automation into more clinical settings, but adoption outside its core accounts is still uneven, so this fits Question Mark territory. In 2024, QIAGEN reported net sales of about $1.97 billion, while its broader automation base is still building beyond established lab customers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge clinical upside\u003c\/li\u003e\n\u003cli\u003eUneven uptake outside core\u003c\/li\u003e\n\u003cli\u003eNeeds more evidence\u003c\/li\u003e\n\u003cli\u003eHigh growth, uncertain share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe big issue is conversion speed, not demand size: if QIAGEN expands clinical pull-through, this can move toward a Star, but weak non-core penetration keeps it a bet, not a winner yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmerging AI-enabled genomics workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAI-assisted genomics is still a developing field, but adoption is rising as labs use software to cut manual review time and raise call accuracy. QIAGEN already has workflow software and sample-to-insight tools, so this could scale into a Star if it wins more users and deepens differentiation. Right now, it fits a Question Mark because growth is real, but share and proof are still building.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowing demand for AI interpretation\u003c\/li\u003e\n\u003cli\u003eQIAGEN has relevant workflow tools\u003c\/li\u003e\n\u003cli\u003eMarket position is still unproven\u003c\/li\u003e\n\u003cli\u003eCan become a Star with wider adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQIAGEN’s Growth Bets: Big Demand, Still Room to Win\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQIAGEN’s Question Marks are growth markets where demand is rising, but share is still not dominant. Liquid biopsy, custom NGS panels, broad oncology assays, automation, and AI genomics all need more scale and proof, even as QIAGEN reported 2024 net sales of US$1.98 billion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquid biopsy\u003c\/td\u003e\n\u003ctd\u003e15%-20% growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e20M cases in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQIAGEN sales\u003c\/td\u003e\n\u003ctd\u003eUS$1.98B in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234906349833,"sku":"qgen-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/qgen-bcg-matrix.webp?v=1785729505","url":"https:\/\/dcfanalyst.com\/products\/qgen-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}